RxDoctor Payments Data

Kimberly Crain, APRN

Psychiatric/Mental Health · Norfolk, VANPI 1669726659

Payments from drug & device makers

$3,622in general payments, 2019–2025

Across 121 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$731
  • Neurocrine Biosciences, Inc.$356
  • Johnson & Johnson$338
  • Otsuka America Pharmaceutical, Inc.$293
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$289
  • Alkermes, Inc.$256
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,622 in reported general payments places this provider in the 85th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$5,207
Medicare patients
20
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$801
Aripiprazole27$768
Bupropion XlBupropion Hcl24$691
Oxcarbazepine16$658
Clonazepam43$473
Quetiapine Fumarate34$458
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$450
Olanzapine22$388
Escitalopram Oxalate49$279
Duloxetine Hcl24$225
Mirtazapine23$219
Trazodone Hcl41$192
Buspirone Hcl20$116
Hydroxyzine Pamoate17$113
Sertraline Hcl34$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$87$10834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →